Monitor for any future conversion of this passive 13G to a 13D, which would signal an activist intent. The unchanged stake at 7.0% suggests no near-term change in the investor's passive posture.
Price Chart
Executive Summary
Freebird Partners LP filed Amendment No. 7 to its Schedule 13G, disclosing beneficial ownership of 119,015 shares (7.0% of the issuer's outstanding common stock, calculated on a diluted basis using 1,699,426 shares outstanding). The stake consists of 52,000 common shares, 52,000 shares issuable upon exercise of common warrants at $17.00 per share, and 15,015 shares issuable upon exercise of pre-funded warrants at $1.875 per share. This is a passive filing with no change in reported ownership from the prior filing; the stake remains unchanged.
Key Financial Metrics
Key Facts
- Freebird Partners LP reports beneficial ownership of 119,015 shares of Ernexa Therapeutics Inc. common stock.
- The stake represents 7.0% of the issuer's outstanding common stock on a diluted basis (1,699,426 shares outstanding).
- Ownership consists of 52,000 common shares, 52,000 common warrants (exercise price $17.00), and 15,015 pre-funded warrants (exercise price $1.875).
- This is Amendment No. 7 to the initial Schedule 13G filed December 2, 2022; the stake appears unchanged from prior filings.
- The filing is made under Rule 13d-1(c) and includes a passive investor certification.
Financial Impact
No material financial impact; passive stake disclosure with no change in ownership.
Risk Factors
- No material risks identified from this routine passive stake amendment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001193125-26-441302 |
| Document: 0001193125-26-441302-index.html | 0001193125-26-441302 |
| Document: 0001193125-26-441302.txt | 0001193125-26-441302 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | SC 13G/A | $2.14 | awaiting T+20 | awaiting T+20 | $1.97 (−7.94%) |
Oct 22, 2026 10d ago | Press Release | $2.08 | awaiting T+20 | awaiting T+20 | $1.97 (−5.06%) |
Oct 15, 2026 17d ago | 8-K | $2.09 | awaiting T+20 | awaiting T+20 | $1.97 (−5.74%) |
Oct 1, 2026 4w ago | Press Release | $2.96 $2.11 | ▼ −28.72% | ▼ −29.42% | $1.97 (−33.45%) |
Sep 30, 2026 4w ago | Press Release | $3.20 $1.99 | ▼ −37.72% | ▼ −38.64% | $1.97 (−38.44%) |
Sep 16, 2026 6w ago | 8-K | $3.76 $2.17 | ▼ −42.29% | ▼ −43.49% | $1.97 (−47.61%) |
Sep 16, 2026 6w ago | 8-K | $3.76 $2.17 | ▼ −42.29% | ▼ −43.49% | $1.97 (−47.61%) |
Jul 14, 2026 15w ago | Press Release | $6.06 $4.39 | ▼ −27.56% | ▼ −30.05% | $1.97 (−67.49%) |
Jun 26, 2026 18w ago | 8-K | $7.03 $3.93 | ▼ −44.10% | ▼ −43.82% | $1.97 (−71.98%) |
Jun 17, 2026 19w ago | Press Release | $5.89 $7.12 | ▲ +20.88% | ▲ +19.57% | $1.97 (−66.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers